PAVmed Has Multiple Paths To Growth 

  • The company has a number of products in various stages of regulatory approval, one of which will start to generate revenue within 2-4 weeks.
  • The company has finance lined up to get it through the regulatory process of two other sizable opportunities.
  • There are several more really sizable opportunities beyond these, and in relation to all this the market cap of the company seems pretty modest.
  • The speed and size of the revenue streams is impossible to foresee at this point and it’s not implausible the company will have to go back to the markets.
  • But they seem to be backed by fairly well disposed capital providers who have put reasonable terms on the financing until now.

Source: PAVmed Has Multiple Paths To Growth – PAVmed Inc. (NASDAQ:PAVM) | Seeking Alpha